Key Metrics of IGC Pharma Inc.
Revenue$1.3M▲ 47.6% YoYFY 2023
Operating income−$9.8M▲ 15.3% YoY
Net profit−$13.0M▼ 13.0% YoY
Shareholders' equity$9.1M
Market cap$25.6MIGC · $0.25
Competitors10identified
About IGC Pharma Inc.
Sectors
Company details
- Listed
- NYSE: IGC
Operational Areas of IGC Pharma Inc.
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameIGC Pharma Inc.
TickerIGC
ExchangeNYSE
CountryUnited States
SEC CIK0001326205
Listed since—
IndustryBiotechnology: Pharmaceutical Preparations
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
IGC · NYSE · SEC CIK 0001326205
Last price · 24 Oct 2026
$0.25
+2.14%
Market cap$25.6M
P/E—On FY 2023 diluted EPS
Volume180,445
SectorHealth CareBiotechnology: Pharmaceutical Preparations
Country · IPOUnited States
IGC share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of IGC Pharma Inc.
Competitors10identified
Countries1most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bio-rad.com | 1980 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.